Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001531569 | SCV001746764 | uncertain significance | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001253773 | SCV002794170 | uncertain significance | Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia | 2021-12-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002570540 | SCV003734970 | uncertain significance | Inborn genetic diseases | 2022-09-26 | criteria provided, single submitter | clinical testing | The c.3887A>G (p.K1296R) alteration is located in exon 38 (coding exon 38) of the DOCK3 gene. This alteration results from a A to G substitution at nucleotide position 3887, causing the lysine (K) at amino acid position 1296 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
OMIM | RCV001253773 | SCV001429646 | pathogenic | Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxia | 2020-08-12 | no assertion criteria provided | literature only |